A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancer

2005 ◽  
Vol 23 (5) ◽  
pp. 479-484 ◽  
Author(s):  
Jaffer A. Ajani ◽  
Chris Takimoto ◽  
Carlos R. Becerra ◽  
Alejandro Silva ◽  
Luis Baez ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase Ii ◽  
Pharmacokinetic Study ◽  
Metastatic Gastric Cancer ◽  
Exatecan Mesylate

Phase II Trial of Etoposide (V), Adriamycin (A), and Cisplatinum (P) in Patients with Metastatic Gastric Cancer

1991 ◽  
Vol 14 (4) ◽  
pp. 357-358 ◽  
Author(s):  
Artur Katz ◽  
Rene C. Gansl ◽  
Sergio D. Simon ◽  
Joaquim Gama-Rodrigues ◽  
Dan Waitzberg ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Metastatic Gastric Cancer

Phase II Trial of 4′-Epi-Doxorubicin in Locally Advanced or Metastatic Gastric Cancer

1988 ◽  
Vol 74 (3) ◽  
pp. 313-315 ◽  
Author(s):  
Eduardo Cazap ◽  
Roberto Estevez ◽  
Mario Bruno ◽  
Daniel Levy ◽  
Carlos Algamiz ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Gastric Adenocarcinoma ◽  
Phase Ii ◽  
Response Rate ◽  
Phase Ii Trial ◽  
Locally Advanced ◽  
Metastatic Gastric Cancer ◽  
Phase Iii ◽  
Future Studies ◽  
Phase Iii Trials

Patients with locally advanced or metastatic gastric adenocarcinoma received an i.v. bolus of 4′-epi-doxorubicin, 75/mg/m2/cycle, every 21 days. Partial responses were observed in 5 of 23 evaluable patients (21.7%). Treatment was generally well tolerated and toxicity was mild. The response rate to epirubicin appears to be very similar to that reported for doxorubicin. Larger doses of epirubicin could be safely used in future studies, and further evaluation of epirubicin in phase III trials is indicated.

Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer

2019 ◽  
Vol 112 ◽  
pp. 20-28
Author(s):  
Chan Kim ◽  
Hong Jae Chon ◽  
Joo Hoon Kim ◽  
Minkyu Jung ◽  
Chung Mo Nam ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Metastatic Gastric Cancer ◽  
Front Line ◽  
Asian Patients

A phase II study of intravenous DX-8951f administered daily for five days every three weeks to patients with previously untreated metastatic gastric cancer

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4126-4126
Author(s):  
C. R. Becerra ◽  
C. Takimoto ◽  
J. A. Ajani ◽  
P. Major ◽  
K. Feit ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Gastric Cancer

A phase II study of weekly docetaxel (T) and capecitabine (X) in patients with metastatic gastric cancer (GC)

2004 ◽  
Vol 22 (14_suppl) ◽  
pp. 4057-4057
Author(s):  
H. K. Kim ◽  
J. H. Chun ◽  
J. S. Lee ◽  
J. Y. Choi ◽  
H. G. Lee ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Metastatic Gastric Cancer ◽  
Weekly Docetaxel
Sign in / Sign up

Export Citation Format

Share Document